GlassScriptPhysician profile
Leon A Cannizzaro
NPI 1356585228
$4,235.57
in general payments reported to CMS, 2019-2025
36 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,335 · 2020: $516 · 2021: $283 · 2022: $585 · 2023: $537 · 2024: $307 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $420.63 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $384.20 | 2019-2020 | |
| Pfizer INC. | $375.76 | 2019-2025 | |
| Amgen INC. | $334.40 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $265.01 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $232.72 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $222.41 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $191.82 | 2021-2023 | Linq II |
| Janssen Pharmaceuticals, INC | $168.70 | 2019-2022 | |
| Abiomed | $164.91 | 2022-2023 | Impella |
| Edwards Lifesciences Corporation | $154.95 | 2025 | Sapien 3 Ultra Resilia, Pascal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.59 | 2019-2025 | Jardiance |
| Abbott Laboratories | $137.86 | 2019-2025 | Mitraclip |
| Astrazeneca Pharmaceuticals LP | $90.05 | 2020-2023 | |
| Arbor Pharmaceuticals, INC. | $89.34 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $77.83 | 2025 | |
| Impulse Dynamics (USA) INC. | $77.43 | 2022-2023 | Optimizer |
| Biosense Webster, INC. | $76.00 | 2024 | Carto 3 |
| Irhythm Technologies, INC. | $70.27 | 2021-2023 | Zio Xt Patch |
| Merck Sharp & Dohme LLC | $63.53 | 2022-2024 | Verquvo |
| Gilead Sciences, INC. | $60.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $47.05 | 2019 | |
| Lundbeck LLC | $41.07 | 2019-2020 | |
| Acutus Medical, INC. | $36.32 | 2020 | |
| Alnylam Pharmaceuticals INC. | $35.73 | 2021-2025 | Amvuttra |
| Chiesi USA, INC. | $34.43 | 2020 | |
| Esperion Therapeutics, INC. | $32.08 | 2020 | |
| Lantheus Medical Imaging, INC. | $28.77 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.45 | 2019 | |
| Astellas Pharma US INC | $24.95 | 2020 | |
| Novo Nordisk INC | $24.37 | 2022 | |
| Akcea Therapeutics, INC. | $23.77 | 2020 | |
| Inari Medical, INC. | $20.75 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Inspire Medical Systems, INC. | $18.96 | 2025 | Inspire |
| Baxter Healthcare | $16.95 | 2022 | |
| Amarin Pharma, INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Cannizzaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.